Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2022-10-28 | Fallopian Tube Neoplasms; Cholangiocarcinoma; Urethral Neoplasms; Microsatellite Instability; Bile Duct Neoplasms; Urologic Neoplasms; Oropharyngeal Neoplasms; Colorectal Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Vulvar Neoplasms; Esophageal adenocarcinoma; Glioma; Gallbladder Neoplasms; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Hepatitis C, Chronic; Cystadenoma, Serous; Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Bone metastases; Kidney Neoplasms; Ovarian Neoplasms; HIV Infections; Stomach Neoplasms; Carcinoma; Vaginal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Cystadenocarcinoma, Serous; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Hydro | Details |
| Cadonilimab | AK-104 | Approved | Zhongshan Akeso Biopharma Co Ltd | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; DNA Repair-Deficiency Disorders; Microsatellite Instability; Lymphoma, T-Cell, Peripheral; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| Ipilimumab | BMS-734016; MDX-CTLA-4; Anti-CTLA-4 Mab; 10D1; MDX-010; MDX-101; Mab-10D14 | Approved | Bristol-Myers Squibb Company | Yervoy | United States | Esophageal Squamous Cell Carcinoma | Bristol-Myers Squibb Company | 2011-03-25 | Testicular Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma; Burkitt Lymphoma; Lung Neoplasms; Brain metastases; Intraocular Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Neoplasms, Gonadal Tissue; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Colorectal Neoplasms; Sezary Syndrome; Primary Myelofibrosis; Sarcoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Nasopharyngeal Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Mycosis Fungoides; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Breast Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Squamous Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Choriocarcinoma; Carcinoma, Embryonal; Leukemia, Myeloid, Acute; Rectal Neoplasms; Neoplasms; Carcinoma, Transitional Cel | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma | Details | |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Genetic Engineering Co Ltd | Melanoma | Details | |
| Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
| BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Melanoma | Details |
| JS-007 | JS-007 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms; Lung Neoplasms; Melanoma | Details |
| CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
| TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
| IMM-27M | IMM27M; IMM-27M | Phase 1 Clinical | Solid tumours | Details | |
| BCD-217 | BCD-217 | Biocad | Details | ||
| Nurulimab | BCD-145 | Biocad | Details | ||
| SI-B003 | SI-B003 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
| RP-2 | RP-2 | Phase 1 Clinical | Replimune, Bristol-Myers Squibb Company | Neoplasms | Details |
| Porustobart | HCAb 4003-2; HBM-4003 | Phase 2 Clinical | Harbour Biomed | Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Solid tumours; Cholangiocarcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| BMS-986249 | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| Davoceticept | ALPN-202 | Phase 1 Clinical | Alpine Immune Sciences Inc | Solid tumours; Lymphoma | Details |
| RIVAL-01 | TBio-6517; TAK-605 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd, Turnstone Biologics Inc | Solid tumours; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Uterine Cervical Neoplasms | Details |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| BA-3071 | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | Beigene Ltd, Bioatla | Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
| Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody, Ludwig Institute For Cancer Research | Solid tumours; Hemangiosarcoma; Carcinoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| XTX-101 | XTX-101 | Phase 2 Clinical | Solid tumours | Details | |
| RP-3 | RP-3 | Phase 1 Clinical | Replimune Inc | Solid tumours | Details |
| FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics Inc | Solid tumours; Neoplasms | Details |
| ADG-116 | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours; Neoplasms | Details |
| Quavonlimab | MK-1308; AK-107 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| KN-044 | KN-044 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| ADG-126 | ADG-126 | Phase 2 Clinical | Adagene Inc | Solid tumours; Neoplasms | Details |
| Erfonrilimab | KN-046; KN046 | Phase 3 Clinical | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details | |
| MEDI-5752 | MEDI-5752 | Phase 1 Clinical | Medimmune Llc | Solid tumours; Carcinoma, Renal Cell | Details |
| IDO-derived peptide vaccine/PD-L1-derived peptide vaccine | IO-102/IO-103 | Phase 3 Clinical | Herlev Hospital | Squamous Cell Carcinoma of Head and Neck; Melanoma | Details |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| Ipilimumab biosimilar (Innovent Biologics) | IBI-310 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Vudalimab | XmAb-20717; XmAb-717 | Phase 2 Clinical | Xencor Inc | Carcinoma, Neuroendocrine; Vulvar Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours | Details |
| YH-001 | YH-001 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Liver Neoplasms; Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis | Details |
| Iparomlimab/Tuvonralimab | QL-1706; PSB-205; PBS-103/PBS-105 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IO-102 | IO-102 | Phase 2 Clinical | Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech Aps | Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell; Mouth Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis | Details |
| GI-101 | SIM-323; SIM323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ONC-392 | ONC-392 | Phase 2 Clinical | Oncoimmune Inc | Carcinoma, Adenoid Cystic; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
| Botensilimab | AGEN-1181 | Phase 2 Clinical | Agenus Inc | Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Hemangiosarcoma; Neoplasms; Colonic Neoplasms; Fibrolamellar hepatocellular carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| CS-1002 | SHR-8068; CS-1002 | Phase 2 Clinical | Cstone Pharmaceuticals | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
